Risankizumab-rzaa (Skyrizi)
Dilution requiredFull monograph review pending
U.S. label preparation
Skyrizi · Dilution required
- Preparation
- For IV induction, add 600 mg for Crohn's disease to 100, 250 or 500 mL of diluent. For ulcerative colitis, add 1,200 mg to 250 or 500 mL. The current U.S. label permits 5% dextrose or 0.9% sodium chloride.
- Administration and handling
- Infuse 600 mg over at least 1 hour and 1,200 mg over at least 2 hours. Use the IV vial and a separate infusion line.
Product and source details
AbbVie Inc. · BLA761262
Product NDC: 0074-5015
SPL effective 2026-10-23 | SPL version 180. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.